These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20717483)

  • 1. Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists.
    Martin FM; Harris AM; Rowland RG; Conner W; Lane M; Durbin E; Baron AT; Kyprianou N
    Gene Ther Mol Biol; 2008; 12(2):253-258. PubMed ID: 20717483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
    Harris AM; Warner BW; Wilson JM; Becker A; Rowland RG; Conner W; Lane M; Kimbler K; Durbin EB; Baron AT; Kyprianou N
    J Urol; 2007 Nov; 178(5):2176-80. PubMed ID: 17870114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
    Benning CM; Kyprianou N
    Cancer Res; 2002 Jan; 62(2):597-602. PubMed ID: 11809715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
    Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N
    Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
    Cuellar DC; Rhee J; Kyprianou N
    Anticancer Res; 2002; 22(3):1673-9. PubMed ID: 12168853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
    Keledjian K; Kyprianou N
    J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No risk of drug-associated liver injury with alpha1-adrenoreceptor blocking agents in men with BPH: results from an observational study using the GPRD.
    Clifford GM; Logie J; Farmer RD
    Pharmacoepidemiol Drug Saf; 2005 Feb; 14(2):75-80. PubMed ID: 15386708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
    Kyprianou N
    J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder.
    Tahmatzopoulos A; Lagrange CA; Zeng L; Mitchell BL; Conner WT; Kyprianou N
    Urology; 2005 May; 65(5):1019-23. PubMed ID: 15882756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
    Kyprianou N; Benning CM
    Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component.
    Anglin IE; Glassman DT; Kyprianou N
    Prostate Cancer Prostatic Dis; 2002; 5(2):88-95. PubMed ID: 12496995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of an α
    Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B
    Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction.
    Partin JV; Anglin IE; Kyprianou N
    Br J Cancer; 2003 May; 88(10):1615-21. PubMed ID: 12771931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic value of quinazoline-based compounds in prostate cancer.
    Bilbro J; Mart M; Kyprianou N
    Anticancer Res; 2013 Nov; 33(11):4695-700. PubMed ID: 24222103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists.
    Björnebo L; Razdan S; Discacciati A; Palsdottir T; Aly M; Nordström T; Eklund M; Lundon D; Grönberg H; Tewari A; Wiklund P; Kyprianou N; Lantz A
    J Natl Cancer Inst; 2024 Sep; 116(9):1459-1465. PubMed ID: 38718219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
    Chrischilles E; Rubenstein L; Chao J; Kreder KJ; Gilden D; Shah H
    Clin Ther; 2001 May; 23(5):727-43. PubMed ID: 11394731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into cardio-oncology: Polypharmacology of quinazoline-based α1-adrenoceptor antagonists.
    Patanè S
    World J Cardiol; 2015 May; 7(5):238-42. PubMed ID: 26015856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of α-adrenoceptor antagonists on prostate cancer development, progression and prevention.
    Wade CA; Goodwin J; Preston D; Kyprianou N
    Am J Clin Exp Urol; 2019; 7(1):46-60. PubMed ID: 30906804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.